Novavax's (NVAX.US) share price jumped more than 20% after the biotech company said Canada had agreed to pay $350 million for Covid vaccines that were previously due to be delivered. The settlement, in the case of NVAX, is significant because the company's management expressed doubts about its viability earlier in the year.
According to the SEC filing, the Canadian government's payment will be made in two equal instalments in 2023. It is worth mentioning that the vaccines for Covid-19 are the company's only commercial product.
The company's shares are currently testing the limitation formed by the 100-day exponential moving average (purple curve). Source: xStation 5
Apple earnings beat Wall Street estimates 🚨 iPhone sales below expectations
🗽S&P 500 companies with the record net margin since 2009 - FactSet data
Market Wrap: UK100 skyrockets after BoE 🇬🇧 🚀 Euphoric gain as ECB Lagarde speaks 🇪🇺 📈
Apple Q2 2026: stable results or the beginning of a new growth cycle?